References
- Nigam SK . The SLC22 transporter family: a paradigm for the impact of drug transporters on metabolic pathways, signaling, and disease. Annu. Rev. Pharmacol. Toxicol.58, 663–687 (2018).
- Li Q , ShuY. Role of solute carriers in response to anticancer drugs. Mol. Cell. Ther.2, 15 (2014).
- Gong S , LuX, XuY, SwiderskiCF, JordanCT, MoscowJA. Identification of OCT6 as a novel organic cation transporter preferentially expressed in hematopoietic cells and leukemias. Exp. Hematol.30(10), 1162–1169 (2002).
- Okabe M , UnnoM, HarigaeHet al. Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem. Biophys. Res. Commun.333(3), 754–762 (2005).
- Novak AJ , AsmannYW, MaurerMJet al. Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma. Blood Cancer J.5, e346 (2015).
- Aouida M , PoulinR, RamotarD. The human carnitine transporter SLC22A16 mediates high affinity uptake of the anticancer polyamine analogue bleomycin-A5. J. Biol. Chem.285(9), 6275–6284 (2010).
- Kunii E , OguriT, KasaiDet al. Organic cation transporter OCT6 mediates cisplatin uptake and resistance to cisplatin in lung cancer. Cancer Chemother. Pharmacol.75(5), 985–991 (2015).
- Wu Y , HurrenR, MacLeanNet al. Carnitine transporter CT2 (SLC22A16) is over-expressed in acute myeloid leukemia (AML) and target knockdown reduces growth and viability of AML cells. Apoptosis20(8), 1099–1108 (2015).
- Shimakata T , KamoshidaS, KawamuraJet al. Immunohistochemical expression profiles of solute carrier transporters in alpha-fetoprotein-producing gastric cancer. Histopathology69(5), 812–821 (2016).
- Uhlen M , FagerbergL, HallstromBMet al. Proteomics. Tissue-based map of the human proteome. Science347(6220), 1260419 (2015).
- Uhlen M , OksvoldP, FagerbergLet al. Towards a knowledge-based Human Protein Atlas. Nat. Biotechnol.28(12), 1248–1250 (2010).
- The Human Protein Atlas . www.proteinatlas.org/.
- UCSC Xena . https://xenabrowser.net/.
- The Human Protein Atlas . Tissue expression of SLC22A16. www.proteinatlas.org/ENSG00000004809-SLC22A16/tissue/stomach; www.proteinatlas.org/ENSG00000004809-SLC22A16/pathology/tissue/stomach+cancer#ihc.
- Carracedo A , CantleyLC, PandolfiPP. Cancer metabolism: fatty acid oxidation in the limelight. Nat. Rev. Cancer13(4), 227–232 (2013).
- Smolkova K , Plecita-HlavataL, BellanceN, BenardG, RossignolR, JezekP. Waves of gene regulation suppress and then restore oxidative phosphorylation in cancer cells. Int. J. Biochem. Cell Biol.43(7), 950–968 (2011).
- Li S , ZhouT, LiCet al. High metastaticgastric and breast cancer cells consume oleic acid in an AMPK dependent manner. PLoS ONE9(5), e97330 (2014).
- Zaugg K , YaoY, ReillyPTet al. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev.25(10), 1041–1051 (2011).
- Zhu XS , GaoP, DaiYC, XieJP, ZengW, LianQN. Attenuation of enoyl coenzyme A hydratase short chain 1 expression in gastric cancer cells inhibits cell proliferation and migration in vitro. Cell. Mol. Biol. Lett.19(4), 576–589 (2014).
- Lal S , WongZW, JadaSRet al. Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics8(6), 567–575 (2007).
- Faraji A , Dehghan ManshadiHR, MobarakiM, ZareM, HoushmandM. Association of ABCB1 and SLC22A16 gene polymorphisms with incidence of doxorubicin-induced febrile neutropenia: a survey of Iranian breast cancer patients. PLoS ONE11(12), e0168519 (2016).